TrialGastroenterology2021
A Phase 1b Safety Study of SER-287, a Spore-Based Microbiome Therapeutic, for Active Mild to Moderate Ulcerative Colitis.
Matthew R Henn et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
66 papers cite itlatest 60 shown
this paperpooled ittrialcites it